Research
Hormonal
Activation of PPARγ by thiazolidinedione (TZD) drugs improves whole-body insulin sensitivity primarily by expanding subcutaneous adipose tissue capacity to sequester free fatty acids, thereby reducing lipotoxicity in skeletal muscle and liver.
If prescribed TZDs, understand that their benefit comes from helping your body store fat safely in the skin rather than letting it damage your liver and muscles. Monitor for swelling, as this is a known side effect linked to how the drug affects kidney sodium handling.
GoodSupportsHIGH confidence
TZDs are predominantly prescribed to enhance insulin sensitivity in patients with type 2 diabetes mellitus... TZDs lead to selective accumulation of subcutaneous adipose tissue... TZDs are likely to act on adipose tissue to enhance its capacity to act as a sump for dietary FFAs, safely sequestering them in adipocytes and partitioning them away from other insulin-sensitive tissues such as skeletal muscle.
Why this rating
Based on large-scale clinical trials and consistent hyperinsulinemic clamp data, though the exact molecular mechanism remains partially debated.
Source
PPAR and human metabolic disease
Robert K. Semple · Journal of Clinical Investigation · 2006
DOI 10.1172/jci28003
narrative_reviewCited 820×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Loss-of-function mutations in PPARγ cause a syndrome of partial lipodystrophy and severe insulin resistance, demonstrating that PPARγ is essential for normal adipose tissue function and metabolic health.Strong
- The PPARγ Pro12Ala polymorphism is associated with a modestly increased risk of type 2 diabetes, but its effect on insulin sensitivity is likely mediated through changes in body mass index (BMI) and adiposity rather than direct metabolic effects.Moderate
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →